| Vision To better personal health and advance personalized medicine by providing genetic based diagnostic solutions th at enable individuals to make better health decisions. Company Pharmigene is founded in 2005 and funded by venture capital firms and individuals. Our goal is to innovate and commercialize diagnostic tests that enables individuals to be better informed about their genomic makeup and to make decisions that better their health. We have licensed exclusive world-wide rights and transferred key know-hows from Academia Sinica relating to the genetic markers that are associated with drug adverse reactions caused by several popular drugs. We have obtained ISO 13485/9001 and GMP certifications, and are manufacturing our DNA genetic tests under the most stringent guideline. In developing our DNA genetic tests, we also have validated our tests with clinical studies that involves hundreds and thousands of patients. Today our DNA genetic tests are available world wide. Specifically several of our tests have CE Marking and have obtain IVD clearance from Department of Health in Taiwan. |
 
|
Milestones
| 2005 | Founded PharmiGene, Inc. |
| 2006 | PharmiGene licensed exclusive world-wide rights to key technologies from Academia Sinica, Taiwan PharmiGene obtained ISO13485/9001 |
| 2007 | FDA approved updated labeling to include pharmacogenomics information pertaining to Coumadin® (warfarin). PharmiGene has the rights to the specifically described genetic marker: vitamin K epoxide reductase (VKORC1) through Academia Sinica. |
| 2008 | PharmiGene received patents “Risk Assessment for Adverse Drug Reactions” issued in USA, Singapore, Taiwan PharmiGene completed manufacturing facility construction PharmiGene received approval from Department of Health, Taiwan, HLA-B*1502 Assessment Test PharmiGene’s HLA-B*1502 Assessment Test was selected as the key screening test for a clinical prospective study that involves 27 hospitals and 4500 patients FDA announced updated labeling to include the association of HLA-B*1502 to Tegretol® (carbamazepine) induced Stevens-Johnson syndrome and toxic epidermal necrolysis PharmiGene has the rights to the specifically described association through Academia Sinica |
| 2009 | PharmiGene obtained GMP certification PharmiGene received CE Marking for HLA-B*1502 Assessment Test, and HLA-B*5801 Assessment Test PharmiGene partners with BioPro Pharmaceutical to enter China market |
| 2010 | PharmiGene partners with Hai Kang Life Corp. to enter Hong Kong market |
Management Team
Y.T. Chen, M.D., Ph.D
Founder
Dr. Y.T. Chen, the scientist who discover the only life-saving treatment for Pompe Disease, has lead the scientific field in another life-saving discoveries: the screening markers for prevention of Stevens-Johnson syndrome induced by drugs such as carbamazepine and allopurinol, and for prediction of warfarin dosage. Dr. Chen is the Director and Distinguished Research Fellow of Academia Sinica, Institute of BioMedical Sciences. Dr. Chen also has a professorship appointment at Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, and has been the Chief of Devision of Medical Genetics from 1994 to 2005. He is also the President of Taiwan Human Genetics Society, and Board of Director of Taiwan Foundation for Rare Disorders. Dr. Chen’s distinguish career also includes many honors and awards, and over 200 scientific publications. He has received his Ph.D. from Columbia University, New York, and M.D. from National Taiwan University, College of Medicine, Taipei, Taiwan.
Luke I. Chen, Ph.D
Chief Executive Officer
Dr. Luke Chen brings years of leadership experience in marketing, sales, business development, product development, manufacturing, licensing and international partnerships. He has a strong track record of achieving sales goals and market share growth, and managing team with diversified technical backgrounds. He is also a member of the Board of Directors of PharmiGene. Prior to his appointment as chief executive officer of PharmiGene, Luke was the Vice President of sales and marketing for Phalanx Biotech Group (PBG) and Vice President of manufacturing. In his tenure at PBG he had lead the company to entered and expanded microarrays ad reagents sales and market share in US, Europe, China, Taiwan, and other regions. He has also held management and marketing positions at Agilent Technologies, Hewlett Packard, Incyte, Clontech, & Scimagix. Luke has received his Ph.D. from University of California, Los Angeles and a BS from University of California, Davis.
Contact us
